DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC BIOMARKER FOR EWING’S SARCOMA

DIAGNOSTICS

Test for determining drug sensitivity and resistance in Ewing’s Sarcoma patients. GSTM4 inhibitor for treatment of drug-resistant Ewing’s Sarcoma.

TECHNOLOGY TYPE

Biomarkers
Therapeutics
Oncology
Ewing’s Sarcoma

STAGE OF DEVELOPMENT

- Inhibition studies demonstrated disruption of GSTM4 decreases chemoresistance.
- Ongoing preclinical testing.

IP PROTECTION

U.S. Utility Patent Issued
Diagnosis and Treatment of Drug-Resistant Ewing’s Sarcoma
US8557532B2

FEATURES AND BENEFITS

- Facilitates earlier and more accurate diagnosis and patient prognosis predictions for Ewing’s Sarcoma.
- Identifies patients who will show first-line drug resistance.
- Provides a novel therapeutic target for second-line treatments.

RECENT PUBLICATIONS


INVENTOR PROFILE

Stephen Lessnick, M.D., Ph.D., Assistant Professor - Oncology

DATE UPDATED: 7/19/2018